Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
The injection is a generic equivalent of the reference listed drug from Fresenius Kabi USA.
The injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA data, the product had US sales of about $71 million for the 12-month period ended March 2026.
Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc.
The company's consolidated net profit rose 17.9% to Rs 163.88 crore while net sales increase 10.1% to Rs 542.77 crore in Q3 FY26 over Q3 FY25.
Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Desmopressin Acetate Injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) DDAVP (desmopressin acetate) Injection, 4 mcg/mL of Nordic Pharma Inc., (NDA 018938).
Desmopressin Acetate Injection is used to treat conditions like haemophilia A, von Willebrand disease, and central diabetes insipidus, helping to manage bleeding and regulate urine production. According to IQVIATM (IMS Health), Desmopressin Acetate injection USP, 4 mcg/mL single-dose vials and 40 mcg/10 mL (4 mcg/mL) multiple-dose vials had US sales of approximately $26 million for the 12-month period ending December 2025.
Sodium Phosphates Injection is indicated as a source of phosphorus for addition to large volume intravenous fluids to prevent or treat hypophosphatemia in patients with limited or no oral intake. It is also used in the preparation of customised parenteral nutrition formulations when standard electrolyte or nutrient solutions are inadequate to meet patient requirements.
According to IQVIA (IMS Health) data, the approved strengths of Sodium Phosphates Injection recorded total US sales of approximately $67 million for the 12-month period ended December 2025.
The counter declined 1.49% to Rs 1,706.90 on the BSE.
Caplin Point Laboratories Ltd, The Bombay Burmah Trading Corporation Ltd, Astrazeneca Pharma India Ltd, Maharashtra Seamless Ltd are among the other stocks to see a surge in volumes on NSE today, 30 December 2025.
Honasa Consumer Ltd registered volume of 193.17 lakh shares by 14:14 IST on NSE, a 27.19 fold spurt over two-week average daily volume of 7.11 lakh shares. The stock rose 5.34% to Rs.291.80. Volumes stood at 10.21 lakh shares in the last session.
Caplin Point Laboratories Ltd witnessed volume of 3.98 lakh shares by 14:14 IST on NSE, a 8.98 times surge over two-week average daily volume of 44277 shares. The stock dropped 6.00% to Rs.1,780.00. Volumes stood at 41821 shares in the last session.
The Bombay Burmah Trading Corporation Ltd registered volume of 3.15 lakh shares by 14:14 IST on NSE, a 7.61 fold spurt over two-week average daily volume of 41410 shares. The stock rose 3.29% to Rs.1,888.80. Volumes stood at 19811 shares in the last session.
Astrazeneca Pharma India Ltd clocked volume of 38380 shares by 14:14 IST on NSE, a 5.47 times surge over two-week average daily volume of 7020 shares. The stock lost 3.02% to Rs.8,770.00. Volumes stood at 8945 shares in the last session.
Maharashtra Seamless Ltd notched up volume of 7.72 lakh shares by 14:14 IST on NSE, a 5.33 fold spurt over two-week average daily volume of 1.45 lakh shares. The stock slipped 0.02% to Rs.551.00. Volumes stood at 1.33 lakh shares in the last session.
Nicardipine Hydrochloride in 0.9% Sodium Chloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. According to IQVIA (IMS Health), Nicardipine Hydrochloride in Sodium Chloride injection had US sales of approximately $68 million for the 12-month period ending August 2025.
The company recently acquired the four approved ANDA products, Icatibant Acetate Injection, Paricalcitol Injection, Gatifloxacin Ophthlamic Solution and Ketamine Hydrochloride Injection from third parties.
According to IQVIA (IMS Health), the collective market size for the above products in the US is approximately $121 million for the 12-month period ending August 2025. These products will be introduced into US and other markets in 2026.
The company reported an 11.2% year-on-year (YoY) increase in revenue from operations to Rs 510.2 crore and a 20.7% YoY rise in profit after tax (PAT) to Rs 150.8 crore in Q1 FY26.
The scrip declined 1.18% to Rs 2002.40 on the BSE.